Allogene Therapeutics Inc (ALLO) Stock Price, Quote & News

Company Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineer...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 457 2700

Website: allogene.com

Address:

210 East Grand Avenue, South San Francisco, United States

tradersunion353 Aug. 23 at 1:36 PM

$ALLO Clowns celebrating for what? Scam is down 99% since IPO insiders CEO,CFO, Directors are bulk selling shares which is huge huge red flag I mean it’s common sense . Until or unless you are paid to pump this thre is nothing bullish here Scam

0 · Reply

SilentScouter Aug. 23 at 5:20 AM

$ALLO Allogene Therapeutics is a clinical stage allogeneic CAR-T company facing significant scientific and regulatory hurdles

1 · Reply

longrigger52 Aug. 22 at 7:24 PM

$ALLO please let us know who we are taking to the 316 prom market is ready to hand us our flower

0 · Reply

SannieVerraderlijk Aug. 22 at 1:04 PM

$ALLO Trading below cash, taking a small position tailcoating the goats. https://hedgefollow.com/funds/Darwin+Global+Management+Ltd

1 · Reply

donotask Aug. 21 at 11:49 AM

$ALLO

0 · Reply

AS1980 Aug. 20 at 5:50 PM

$ALLO how fckn boring

1 · Reply

tradersunion353 Aug. 19 at 5:44 PM

$ALLO Beware of this scam. Dont fall for pumpers

0 · Reply

tradersunion353 Aug. 19 at 1:49 PM

$ALLO Just wondering who are these folks still celebrating this pos stock moves Until or unless you are paid to pump this pos . No real trader will celebrate this scam losing 99% share value and heavy insider selling

0 · Reply

tradersunion353 Aug. 19 at 1:36 AM

$ALLO Scam is almost dead. $48 to 1 dollar drop was cake walk Now already to drop to 50 cents Get ready for reverse split

0 · Reply

donotask Aug. 18 at 5:10 PM

$ALLO fukin sharks‼️🤣🤣🤣

0 · Reply

Allogene Therapeutics: Important Catalysts Guided For Early 2026

Aug 13, 2025, 9:13 PM EDT - 10 days ago

Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:05 PM EDT - 10 days ago

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Aug 6, 2025, 8:30 AM EDT - 18 days ago

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Aug 1, 2025, 8:30 AM EDT - 23 days ago

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Jun 1, 2025, 10:45 AM EDT - 2 months ago

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

May 29, 2025, 3:37 PM EDT - 3 months ago

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

May 28, 2025, 9:43 AM EDT - 3 months ago

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

May 23, 2025, 8:30 AM EDT - 3 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

May 22, 2025, 5:17 PM EDT - 3 months ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 13, 2025, 10:47 PM EDT - 3 months ago

Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 3 months ago

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

May 6, 2025, 8:30 AM EDT - 3 months ago

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Apr 23, 2025, 10:12 AM EDT - 4 months ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 7, 2025, 8:30 AM EDT - 4 months ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Mar 13, 2025, 11:56 PM EDT - 5 months ago

Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:02 PM EDT - 5 months ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Mar 3, 2025, 8:30 AM EST - 6 months ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Feb 26, 2025, 10:52 AM EST - 6 months ago

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Feb 26, 2025, 8:30 AM EST - 6 months ago

Allogene Therapeutics Announces Participation in March Investor Conference

Feb 25, 2025, 4:10 PM EST - 6 months ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 24, 2025, 10:53 PM EST - 6 months ago

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

$Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology$

Feb 13, 2025, 4:30 PM EST - 6 months ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Jan 28, 2025, 8:30 AM EST - 7 months ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Dec 16, 2024, 8:30 AM EST - 8 months ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2024, 8:30 AM EST - 9 months ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Nov 19, 2024, 8:30 AM EST - 9 months ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Nov 18, 2024, 8:30 AM EST - 9 months ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Nov 7, 2024, 8:59 PM EST - 10 months ago

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:02 PM EST - 10 months ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Nov 7, 2024, 10:00 AM EST - 10 months ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Nov 5, 2024, 9:10 AM EST - 10 months ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 30, 2024, 8:30 AM EDT - 10 months ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Oct 2, 2024, 4:11 PM EDT - 11 months ago

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Sep 30, 2024, 8:30 AM EDT - 11 months ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Aug 26, 2024, 11:39 PM EDT - 1 year ago

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Aug 10, 2024, 12:34 AM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Jul 1, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Jun 12, 2024, 1:09 PM EDT - 1 year ago

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

May 23, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

May 13, 2024, 7:31 PM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:47 PM EDT - 1 year ago

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

May 13, 2024, 4:01 PM EDT - 1 year ago

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

May 6, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Apr 26, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Apr 9, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Q2 Investor Conference Participation

Apr 4, 2024, 11:30 AM EDT - 1 year ago

Showcasing Seeking Alpha's March 2024 New Analysts

APD AXP CPS CPT DG DK EPR

tradersunion353 Aug. 23 at 1:36 PM

0 · Reply

SilentScouter Aug. 23 at 5:20 AM

$ALLO Allogene Therapeutics is a clinical stage allogeneic CAR-T company facing significant scientific and regulatory hurdles

1 · Reply

longrigger52 Aug. 22 at 7:24 PM

$ALLO please let us know who we are taking to the 316 prom market is ready to hand us our flower

0 · Reply

SannieVerraderlijk Aug. 22 at 1:04 PM

$ALLO Trading below cash, taking a small position tailcoating the goats. https://hedgefollow.com/funds/Darwin+Global+Management+Ltd

1 · Reply

donotask Aug. 21 at 11:49 AM

$ALLO

0 · Reply

AS1980 Aug. 20 at 5:50 PM

$ALLO how fckn boring

1 · Reply

tradersunion353 Aug. 19 at 5:44 PM

$ALLO Beware of this scam. Dont fall for pumpers

0 · Reply

tradersunion353 Aug. 19 at 1:49 PM

0 · Reply

tradersunion353 Aug. 19 at 1:36 AM

$ALLO Scam is almost dead. $48 to 1 dollar drop was cake walk Now already to drop to 50 cents Get ready for reverse split

0 · Reply

donotask Aug. 18 at 5:10 PM

$ALLO fukin sharks‼️🤣🤣🤣

0 · Reply

Taurusthebullman Aug. 18 at 3:48 PM

$ALLO so then, what is motivating you to post SO MANY times per day I wonder?👇

0 · Reply

tradersunion353 Aug. 18 at 3:29 PM

$ALLO What did i warn about this scam and pumpers on this board Be extremely extremely careful here

0 · Reply

tradersunion353 Aug. 18 at 3:05 PM

$ALLO If you want to lose your money please invest in ALLO I am surprised people on this board who are paid to pump this stock have no morale when insiders are crazily selling this stock. These paid pumpers are pumping this garbage

1 · Reply

tradersunion353 Aug. 18 at 2:13 PM

$ALLO Scam. Heading to 50 cents

0 · Reply

tradersunion353 Aug. 17 at 6:42 PM

$ALLO Scam

1 · Reply

dbr_island Aug. 15 at 8:43 PM

HERZ 👈 🚢📦📦📦📦📦📦📦📦🚨 WHO IS READY FOR BIG GAINS Like THIS BELOW $DHAI $TOVX $PPCB $ALLO $IRWD let’s get it

0 · Reply

tradersunion353 Aug. 15 at 5:58 PM

$ALLO I warned multiple times about this scam here Run away before it takes away all your money

0 · Reply

donotask Aug. 15 at 5:44 PM

$ALLO not full yet‼️

0 · Reply

tradersunion353 Aug. 15 at 4:34 PM

$ALLO Will close red

0 · Reply

tradersunion353 Aug. 15 at 3:30 PM

$ALLO Run away before this scam takes all your money.

0 · Reply

tradersunion353 Aug. 15 at 3:29 PM

$ALLO Pos lost half the gains Will close red

0 · Reply

tradersunion353 Aug. 15 at 3:15 PM

$ALLO What are these clowns celebrating for ? Pos lost 99% share value Insiders are selling crazily at $1 range Earnings were ugly Lost 50% value in 3 months I mean until or unless you are paid to pump this scam nobody sees this bullish

0 · Reply

Market Cap	264.04M
Revenue (ttm)	20,000.00
Net Income (ttm)	-257.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,287,950.01%
Debt to Equity Ratio	0.00

Volume	7,303,000
Avg Vol	4,242,746
Day's Range	N/A - N/A
Shares Out	221.88M
Stochastic %K	83%
Beta	0.35
Analysts	Strong Sell
Price Target	$7.65